Abraxane (Breast Cancer) - Analysis and Forecasts to 2020

NEW YORK, Feb. 7, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0657216/Abraxane-Breast-Cancer-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Abraxane (Breast Cancer) – Analysis and Forecasts to 2020

- Analysis and review of Abraxane including sales data

- Qualitative and quantitative assessment of market space

- Analysis of the trends, drivers and restraints shaping and defining the markets

- In-depth analysis of Abraxane including efficacy, safety, pricing, competition and other details which influence its sales potential

- Detailed sales forecasts from 2005-2017 for Abraxane in the seven major markets

- Stay ahead of competition by understanding the changing competitive landscape

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of the drug's performance

- Examine the historical sales performance of a drug in seven major markets

- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Table of Contents1 Table of Contents 21.1 List of Tables 31.2 List of Figures 42 Intro duction 52.1 Breast Cancer Market 52.2 Epidemiology 52.3 Etiology and Risk Factors 72.3.1 Age and Gender 72.3.2 Genetic Inheritance 72.3.3 Hormone Replacement Therapy 72.3.4 Radiation 72.3.5 Obesity 72.3.6 Alcohol Consumption 72.3.7 Late Child Birth 72.3.8 Use of Birth Control Pills 72.4 GlobalData Report Guidance 83 Breast Cancer: Market Characterization 93.1 Breast Cancer Market 93.2 Breast Cancer Market Forecasts and CAGR 93.3 Drivers of Breast Cancer Market 103.3.1 Breast Cancer: Most Frequent Cancer in Women 103.3.2 Increasing Breast Cancer Incidence Rate 103.3.3 Decreasing Breast Cancer Mortality Rate 123.3.4 High Survival Rates of Breast Cancer 144 Staging of Breast Cancer: Introduction 154.1 Distribution of Patients by Stages 154.1.1 Stages 155 Predictive Biomarker in the Treatment of Breast Cancer 176 Treatment Options of Breast Cancer 196.1 Stage 0 Breast Cancer 196.2 Early Stage Breast Cancer (Excluding Stage 0) 206.3 Metastatic Breast Cancer (MBC) 226.3.1 Endocrine Treatment: Adjuvant, First Line and Second Line 226.3.2 Cytotoxic Chemotherapy 246.3.3 Management of Patients with HER-2 Positive Patients 267 Abraxane 287.1 Introduction 287.2 Mechanism of Action 287.3 Clinical Studies 287.4 Approval History of Abraxane 297.5 Factors Affecting Sales of Abraxane 297.5.1 No Premedication Required to Prevent Solvent-Related Hypersensitivity 297.5.2 Patent Expiry of Abraxane 297.5.3 Competition from Generics 297.6 Drug Evaluation 307.6.1 Drug Risk Benefit Score 307.6.2 Intensity of Competition 307.7 Sales Forecast 317.7.1 Target Patient Pool of Abraxane 317.7.2 Dosing 317.7.3 Market Penetration 317.7.4 Annual Cost of Therapy 327.7.5 Sales Projections of Abraxane 328 Appendix 418.1 Market Definitions 418.2 Abbreviations 418.3 Research Methodology 418.3.1 Coverage 418.3.2 Secondary Research 428.3.3 Forecasting 428.3.4 Number of Patients Approved to Take the Drug 428.3.5 Net Penetration of Drug 438.3.6 Net Annual Dosing 438.3.7 Annual Cost of Therapy 438.4 Drug Sales Estimates Model 438.5 Contact Us 438.6 Disclaimer 448.7 Sources 44

List of Tables

Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5Table 2: Five-Year Relative Survival Rates, 2005, By Stages 14Table 3: Efficacy Results of Phase III trial of Abraxane 29Table 4: Approval History of Abraxane 29Table 5: Drug Risk Benefit Score of Abraxane 30Table 6: Abraxane, Breast Cancer, Global, Annual Cost of Therapy ($), 2011 32Table 7: Abraxane, Breast Cancer, Global Sales Estimates ($m), 2005–2020 33Table 8: Abraxane, Breast Cancer, The US, Sales Estimates ($m), 2005–2020 33Table 9: Abraxane, Breast Cancer, the UK, Sales Estimates ($m), 2009–2020 34Table 10: Abraxane, Breast Cancer, France, Sales Estimates ($m), 2009–2020 35Table 11: Abraxane, Breast Cancer, Germany, Sales Estimates ($m), 2009–2020 36Table 12: Abraxane, Breast Cancer, Italy, Sales Estimates ($m), 2009–2020 37Table 13: Abraxane, Breast Cancer, Spain, Sales Estimates ($m), 2009–2020 38Table 14: Abraxane, Breast Cancer, Japan, Sales Estimates ($m), 2010–2020 39

List of Figures

Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 6Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 2010–2020 9Figure 3: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 11Figure 5: Breast Cancer, Incidence, Worldwide, 2008-2030 11Figure 6: All Cancers, Incidence, Worldwide, 2008-2030 12Figure 7: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12Figure 8: Breast Cancer, Mortality, Worldwide, 2008-2030 13Figure 9: All Cancers, Mortality, Worldwide, 2008-2030 13Figure 10: Broad Classification of Breast Cancer, By Type 15Figure 11: Classification of Non-Invasive Breast Cancer, By CIS 15Figure 12: Classification of Invasive Breast Cancer, By Stages 16Figure 13: Classification of Invasive Breast Cancer, By Treatment 16Figure 14: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 17Figure 15: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC 18Figure 16: Breast Cancer Types in Decreasing Order of their Aggressiveness 18Figure 17: Treatment Options, DCIS Breast Cancer 19Figure 18: Treatment Options, LCIS Breast Cancer 20Figure 19: Classification of Stages I, II and IIIA 20Figure 20: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 21Figure 21: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 21Figure 22: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 22Figure 23: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 23Figure 24: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 23Figure 25: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 25Figure 26: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 26Figure 27: Drug Model Diagram of Abraxane 31Figure 28: Abraxane, Breast Cancer, Global, Sales Estimates ($m), 2005–2020 32Figure 29: Abraxane, Breast Cancer, the US, Sales Estimates ($m), 2005–2020 33Figure 30: Abraxane, Breast Cancer, the UK, Sales Estimates ($m), 2009–2020 34Figure 31: Abraxane, Breast Cancer, France, Sales Estimates ($m), 2009–2020 35Figure 32: Abraxane, Breast Cancer, Germany, Sales Estimates ($m), 2009–2020 36Figure 33: Abraxane, Breast Cancer, Italy, Sales Estimates ($m), 2009–2020 37Figure 34: Abraxane, Breast Cancer, Spain, Sales Estimates ($m), 2009–2020 38Figure 35: Abraxane, Breast Cancer, Japan, Sales Estimates ($m), 2010–2020 39Figure 36: Abraxane, Breast Cancer, Global, Sales Distribution by Country (%), 2020 40Figure 37: Patients Approved for the Drug 42

More  

Check our  

CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker